NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment - Guidance development

STA Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential issues were identified during scoping.

- 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
 - 1. It was highlighted that some people with ovarian cancer may struggle to access treatments if they do not fully understand the treatment options and choices. This may include people with learning disabilities, people who have English as a second language or who have low levels of literacy. The committee considered that people would not be disadvantaged by the recommendations, providing that clinicians act in the interest of the people having treatment, in line with their usual responsibilities, and tailor their explanation to each person's level of understanding, and discuss the risks and benefits with the person's carers when applicable. The committee concluded that there was no need to alter or add to its recommendations.
 - It was also highlighted that, in general terms, older patients with cancer are frequently disadvantaged and frequently not offered the

Issue date: July 2024

same intensity treatment. This was acknowledged by the committee but it did not consider it to be an equality issue that could be resolved by this appraisal.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equalities issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Issue date: July 2024

Equality issues considered by the committee are included in section 3.22 of the draft guidance document.

Approved by Associate Director (name):Janet Robertson......

Date: 24/06/2024

platinum-based chemotherapy 3 of 3 Issue date: July 2024